Abstract: The present disclosure relates to methods for treating or preventing immune-mediated pulmonary injury (IMPI) in a subject in need thereof, the method comprising administering to the subject an anti-Type I interferon (anti-T1i) therapy that blocks the activity, function or production of Type I interferon (T1i) in the subject, wherein the anti-T1i therapy is administered to the subject infected with a respiratory virus that causes a delayed T1i response in the subject.

Abstract: The present invention relates to the use of components of the IL23 pathway as biomarkers, e.g., IL22, LCN2 and combinations thereof, to stratify or identify populations of patients suffering from IL23-mediated diseases (e.g., Crohn's disease) responsive to treatment with an anti-IL23 antagonist (including, e.g., anti-IL23 antibodies or antigen-binding fragments thereof). Levels of IL23 pathway biomarkers above or below a predetermined threshold can be used, for example, (i) to determine whether a patient with an IL23-mediated disease or disorder such a Crohn's disease is eligible or non-eligible for treatment with a therapeutic agent (e.g., an anti-IL23 antibody), (ii) to determine whether treatment with a certain agent should be commenced, suspended, or modified, (iii) to diagnose whether the IL23-mediated disease is treatable or not treatable with a specific therapeutic agent, or (iv) to predict the outcome of treating the IL23-mediated disease with a specific therapeutic agent.

Abstract: The present invention relates to the use of the Chemokine (C—C motif) ligand 20 (CCL20) as a biomarker to stratify or identify populations of patients suffering from interleukin-23 (IL23)-mediated diseases (e.g., Crohn's disease) responsive to treatment with an, anti-IL23 antagonist (including, e.g., anti-IL23 antibodies). Levels of CCL20 above or below a predetermined threshold can be used, for example, (i) to determine whether a patient with an IL23-mediated disease or disorder such a Crohn's disease is eligible or non-eligible for treatment with a therapeutic agent, (ii) to determine whether treatment with a certain agent should be commenced, suspended, or modified, (iii) to diagnose whether the IL23-mediated disease is treatable or not treatable with a specific therapeutic agent, or (iv) to predict the outcome of treating the IL23-mediated disease with a specific therapeutic agent. CCL20 can be used in combination with other IL23 pathway biomarkers such as IL22 and/or lipocalin-2 (LCN2).

Abstract: The present invention relates to the use of the Chemokine (C—C motif) ligand 20 (CCL20) as a biomarker to stratify or identify populations of patients suffering from interleukin-23 (IL23)-mediated diseases (e.g., Crohn's disease) responsive to treatment with an, anti-IL23 antagonist (including, e.g., anti-IL23 antibodies). Levels of CCL20 above or below a predetermined threshold can be used, for example, (i) to determine whether a patient with an IL23-mediated disease or disorder such a Crohn's disease is eligible or non-eligible for treatment with a therapeutic agent, (ii) to determine whether treatment with a certain agent should be commenced, suspended, or modified, (iii) to diagnose whether the IL23-mediated disease is treatable or not treatable with a specific therapeutic agent, or (iv) to predict the outcome of treating the IL23-mediated disease with a specific therapeutic agent. CCL20 can be used in combination with other IL23 pathway biomarkers such as IL22 and/or lipocalin-2 (LCN2).

Abstract: The present invention relates to the use of components of the IL23 pathway as biomarkers, e.g., IL22, LCN2 and combinations thereof, to stratify or identify populations of patients suffering from IL23-mediated diseases (e.g., Crohn's disease) responsive to treatment with an anti-IL23 antagonist (including, e.g., anti-IL23 antibodies or antigen-binding fragments thereof). Levels of IL23 pathway biomarkers above or below a predetermined threshold can be used, for example, (i) to determine whether a patient with an IL23-mediated disease or disorder such a Crohn's disease is eligible or non-eligible for treatment with a therapeutic agent (e.g., an ant-IL23 antibody), (ii) to determine whether treatment with a certain agent should be commenced, suspended, or modified, (iii) to diagnose whether the IL23-mediated disease is treatable or not treatable with a specific therapeutic agent, or (iv) to predict the outcome of treating the IL23-mediated disease with a specific therapeutic agent.

Abstract: The present invention relates to the use of the Chemokine (C—C motif) ligand 20 (CCL20) as a biomarker to stratify or identify populations of patients suffering from interleukin-23 (IL23)-mediated diseases (e.g., Crohn's disease) responsive to treatment with an, anti-IL23 antagonist (including, e.g., anti-IL23 antibodies). Levels of CCL20 above or below a predetermined threshold can be used, for example, (i) to determine whether a patient with an IL23-mediated disease or disorder such a Crohn's disease is eligible or non-eligible for treatment with a therapeutic agent, (ii) to determine whether treatment with a certain agent should be commenced, suspended, or modified, (iii) to diagnose whether the IL23-mediated disease is treatable or not treatable with a specific therapeutic agent, or (iv) to predict the outcome of treating the IL23-mediated disease with a specific therapeutic agent. CCL20 can be used in combination with other IL23 pathway biomarkers such as IL22 and/or lipocalin-2 (LCN2).

Abstract: A mobile computing device is disclosed. In some aspects, the mobile computing device may execute a first application using one or more processors, and may receive, during execution of the first application, a user selection of a shift key. The mobile computing device may transition a state of the shift key from an unlocked non-shift state to a shift state based on the user selection. The mobile computing device may change the execution of the first application to an execution of a second application, and clear the state of the shift key in response to changing the execution from the first application to the second application.

Abstract: A mobile computing device is disclosed. In some aspects, the mobile computing device may execute a first application using one or more processors, and may receive, during execution of the first application, a user selection of a shift key. The mobile computing device may transition a state of the shift key from an unlocked non-shift state to a shift state based on the user selection. The mobile computing device may change the execution of the first application to an execution of a second application, and clear the state of the shift key in response to changing the execution from the first application to the second application.

Abstract: A mobile computing device is disclosed. In some aspects, the mobile computing device may execute a first application using one or more processors, and may receive, during execution of the first application, a user selection of a shift key. The mobile computing device may transition a state of the shift key from an unlocked non-shift state to a shift state based on the user selection. The mobile computing device may change the execution of the first application to an execution of a second application, and clear the state of the shift key in response to changing the execution from the first application to the second application.

Abstract: The present invention relates to the use of components of the IL23 pathway as biomarkers, e.g., IL22, LCN2 and combinations thereof, to stratify or identify populations of patients suffering from IL23-mediated diseases (e.g., Crohn's disease) responsive to treatment with an anti-IL23 antagonist (including, e.g., anti-IL23 antibodies or antigen-binding fragments thereof). Levels of IL23 pathway biomarkers above or below a predetermined threshold can be used, for example, (i) to determine whether a patient with an IL23-mediated disease or disorder such a Crohn's disease is eligible or non-eligible for treatment with a therapeutic agent (e.g., an ant-IL23 antibody), (ii) to determine whether treatment with a certain agent should be commenced, suspended, or modified, (iii) to diagnose whether the IL23-mediated disease is treatable or not treatable with a specific therapeutic agent, or (iv) to predict the outcome of treating the IL23-mediated disease with a specific therapeutic agent.

Abstract: There is provided a method of treating a subject afflicted with a condition that is associated with inappropriate trafficking of cells expressing alpha4beta7 to the gastrointestinal tract, comprising administering to the subject an alpha4beta7 heterodimer specific antibody in an amount and at an interval sufficient to ameliorate the condition.

Abstract: A mobile computing device is disclosed. In some implementations, the mobile computing device may receive, from a user, an input character string for presentation on a touch-sensitive display of the mobile computing device, may select a replacement character string based on the input character string, and may replace the input character string with the selected replacement character string. In some aspects, the input character string may be a misspelled word and the replacement character string may be a correctly spelled version of the misspelled word. In other aspects, the input character string may be an abbreviation and the replacement character string may be a completed version of the abbreviation.

Abstract: A mobile computing device is disclosed. In some aspects, the mobile computing device may execute a first application using one or more processors, and may receive, during execution of the first application, a user selection of a shift key. The mobile computing device may transition a state of the shift key from an unlocked non-shift state to a shift state based on the user selection. The mobile computing device may change the execution of the first application to an execution of a second application, and clear the state of the shift key in response to changing the execution from the first application to the second application.

Abstract: Described herein is a computer-implemented system and method for processing one or more alternate symbols associated or linked to a base symbol. A base symbol is a symbol to which at least one alternate symbol is linked. A base symbol commonly appears on a key of a keyboard or a display of a keyboard, or is a handwritten symbol recognized by handwriting entry software. Examples of alternate symbols are accented characters and punctuation marks that do not appear on a keyboard or are not commonly recognized by a handwriting entry program, and short symbol sequences. An example of a common short symbol sequence is an emoticon used in e-mail messages to convey tone or feelings. An example of a computer device that may embody the system or method is a hand-held computing device.

Abstract: An integrated device provides functionality of both a PDA and cellular telephone. Features include a power button offering control of both the computing and telephony functions of the device; a lid that turns the device on and off and controls additional telephony functions; a jog rocker that activates the device and is used to select from a variety of menu options; application buttons that offer direct access to applications stored on the device, and which can be configured to operate in conjunction with secondary keys to offer added functionality; a keyboard that enables data input into the device; an automatic word completion function that verifies and corrects a user's typing in real time; and a simplified keyboard navigation system that allows the navigation of menus using keyboard shortcuts.

Abstract: A system for displaying high resolution images on a high resolution display system includes a network server, a first electronic device, and a high resolution display. The network server includes an image library database including multiple coded image files, and a display module for transmitting display information in response to a display request. Each image file is configured to be decoded into a video image data stream when a decoder executable file is executed by a processor, is created from one or more high resolution image files with a coder executable file, includes all of the image data included in each high resolution image file, and has a size smaller than the total size of all the one or more high resolution image files. The video image data stream includes all the image data of the one or more high resolution image files. The display module includes information on the coded image files included in the image library database; and a user interface for selecting and downloading coded image files.

Abstract: An integrated device provides functionality of both a PDA and cellular telephone. Features include a power button offering control of both the computing and telephony functions of the device; a lid that turns the device on and off and controls additional telephony functions; a jog rocker that activates the device and is used to select from a variety of menu options; application buttons that offer direct access to applications stored on the device, and which can be configured to operate in conjunction with secondary keys to offer added functionality; a keyboard that enables data input into the device; an automatic word completion function that verifies and corrects a user's typing in real time; and a simplified keyboard navigation system that allows the navigation of menus using keyboard shortcuts.

Abstract: An integrated device provides functionality of both a PDA and cellular telephone. Features include a power button offering control of both the computing and telephony functions of the device; a lid that turns the device on and off and controls additional telephony functions; a jog rocker that activates the device and is used to select from a variety of menu options; application buttons that offer direct access to applications stored on the device, and which can be configured to operate in conjunction with secondary keys to offer added functionality; a keyboard that enables data input into the device; an automatic word completion function that verifies and corrects a user's typing in real time; and a simplified keyboard navigation system that allows the navigation of menus using keyboard shortcuts.

Abstract: An integrated device provides functionality of both a PDA and cellular telephone. Features include a power button offering control of both the computing and telephony functions of the device; a lid that turns the device on and off and controls additional telephony functions; a jog rocker that activates the device and is used to select from a variety of menu options; application buttons that offer direct access to applications stored on the device, and which can be configured to operate in conjunction with secondary keys to offer added functionality; a keyboard that enables data input into the device; an automatic word completion function that verifies and corrects a user's typing in real time; and a simplified keyboard navigation system that allows the navigation of menus using keyboard shortcuts.

Abstract: Described herein is a computer-implemented system and method for processing one or more alternate symbols associated or linked to a base symbol. A base symbol is a symbol to which at least one alternate symbol is linked. A base symbol commonly appears on a key of a keyboard or a display of a keyboard, or is a handwritten symbol recognized by handwriting entry software. Examples of alternate symbols are accented characters and punctuation marks that do not appear on a keyboard or are not commonly recognized by a handwriting entry program, and short symbol sequences. An example of a common short symbol sequence is an emoticon used in e-mail messages to convey tone or feelings. An example of a computer device that may embody the system or method is a hand-held computing device.